Multiple studies have shown that TP53 mutations can be used as a poor prognostic factor in metastatic NSCLC, and mutations in exons at different sites have different effects on clinical prognosis in clinical studies with small samples [38,39,40,41]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.